Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.
Evozyne has raised $81.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.
Evozyne's investors include Valor Equity Partners, OrbiMed, Fidelity, Paragon Biosciences, NVentures.
Evozyne is headquartered in Chicago, United States.
Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.
Evozyne is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Evozyne — Funding & Investors." VCBacked, September 27, 2023, https://www.vcbacked.co/company/evozyne. Accessed October 31, 2026.
VCBacked. (2023). Evozyne — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/evozyne
{{cite web |title=Evozyne — Funding & Investors |url=https://www.vcbacked.co/company/evozyne |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated